Physicians' Academy for Cardiovascular Education

Landmark study with PCSK9 inhibitor will change clinical practice

Mar. 18, 2017 - Prof. Eric Bruckert - Pitié-Salpêtrière Hospital, Paris, France - ACC 2017, Washington DC, USA

PCSK9 Expert Opinions According to prof. Eric Bruckert, FOURIER is a landmark study that will change clinical practice, especially for patients with the highest risk.

Educational information

This educational video is part of a series of PCSK9 Expert Opinions that are aimed to provide different perspectives and opinions from international experts in this field and may provide support with the interpretation and translation of new findings towards implications for clinical practice

The educational content reflects the personal opinion of the experts and is recorded as an independent educational service by PACE-CME

Faculty & Disclosures

Prof. Eric Bruckert - Pitié-Salpêtrière Hospital, Paris, France


Funding was provided by an unrestricted educational grant from Amgen